Alumis Past Earnings Performance
Past criteria checks 0/6
Alumis's earnings have been declining at an average annual rate of -65.7%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually.
Key information
-65.7%
Earnings growth rate
78.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -68.5% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Alumis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -239 | 29 | 213 |
| 30 Jun 24 | 0 | -189 | 25 | 163 |
| 31 Mar 24 | 0 | -169 | 22 | 147 |
| 31 Dec 23 | 0 | -155 | 20 | 138 |
Quality Earnings: ALMS is currently unprofitable.
Growing Profit Margin: ALMS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if ALMS's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare ALMS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALMS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: ALMS has a negative Return on Equity (-68.54%), as it is currently unprofitable.